Mass spectrometry-based proteomics are used to identify biomarkers in Alzheimer’s Disease (AD) and to establish how these biomarkers change in the brain during disease progression. The study of peptides, proteomics and metabolomics can provide clues to early detection and treatment strategies of this chronic and destructive disease. Give us a call at 972-668-6005 with any questions you might have.